KTH Royal Institute of Technology at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
KTH Royal Institute of Technology brings 5 presentations to ESGCT 2026 in Hamburg. Its work centres on small binding proteins that retarget lentiviral vectors to chosen cells, extended to a whole-body platform for selective gene therapy. A second strand examines what limits AAV output in producer cells, including differences between HEK293 lines.
| Organization | ESGCT 2026 Attendance |
|---|---|
KTH Royal Institute of Technology Stockholm, Sweden | |
Poster Wed Oct 28 1:30pm–3:30pm A novel Affibody-based platform for cell-specific retargeting of lentiviral vectors Poster Wed Oct 28 1:30pm–3:30pm Multi-parametric characterization of rAAV production as a guide towards better producer cells Poster Thu Oct 29 2:00pm–4:00pm A whole body-scale Affibody-based platform for cell-selective in vivo gene therapy Poster Thu Oct 29 2:00pm–4:00pm Addition of an extra plasmid containing a viral helper gene positively impacts triple transfection-based rAAV production in HEK293 cells Poster Thu Oct 29 2:00pm–4:00pm Dissecting AAV serotype divergent capsid regions impacting secretory differences across HEK293 cell lines |
Instantly find 20 buyers from KTH Royal Institute of Technology
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction